life scienc tool diagnost earn
ep consensu tmo ep beat
estim better revenu profit factor line ad
howev provid new guidanc updat thought
impact dynam still broadli unknown lower ep
predic weaker revenu growth due
dynam particularli across analyt instrument busi lower profit
revenu top-end pre-announce rang organ revenu
estim within pre-announce rang experienc
strength life scienc solut vs estimate specialti diagnost vs estimate
laboratori product servic vs estimate partial off-set weaker
expect growth across vs estimate gross margin
contract bp bp plan oper expens fell bp
bp better view net/net ebitda margin fell bp albeit bp plan
billion help fund dividend repurchas
pre-cal view share may rise reiter neutral share
ytd vs share may rise today strong oper perform
across busi unit despit weak across
weak rel unsurpris deferr cancel capital-equip
purchas uncertain macroeconom backdrop said overal top-line
organ growth essenti line prior pre-announce
importantli updat tmo expect withdrew guidanc
await commentari confer call broader landscap
challeng nt encourag tmo abil effici innov covid-
environ gener posit bias pend acquisit
still slate close said share still trade ev/ebitda multipl
well histor averag life scienc peer group averag
view share adequ reflect longer term organ growth prospect
strengthen margin profil upsid current valuat level limit
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
mariu zoican univers toronto rotman school manag april
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
thermo fisher lead provid instrument reagent
consum softwar servic custom span
biopharmaceut diagnost academic/government
blue sky scenario predic organ growth
upper end current lt target faster margin expans
thereon support oper leverag ppi initi
share grey sky scenario predic organ growth
lower end current lt target predic slow
fund growth stringent regulatori environ particularli
custom consolid continu compound potenti slower
expect margin expans thereon
 close
mariu zoican univers toronto rotman school manag april
compani mention price
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
